ISSN 1612-3352

Editors in Chief

Prof. Dr. Claus F. Claussen, Neurootological Research Institute of the Research Society for Smell, Taste, Hearing and Equilibrium Disorders at Bad Kissingen (4-G-F). Bad Kissingen, Germany.
Dr. med. Julia M. Bergmann,
Dr. med. Guillermo O. Bertora,
Otoneuroophthalmological Neurophysiology,
Buenos Aires, Argentina.

Production Managers

Dr. med. Julia M. Bergmann,
Dr. med. Guillermo O. Bertora,
Otoneuroophthalmological Neurophysiology,
Buenos Aires, Argentina.


Associated Editors


The editors welcome authors to submit articles for publications in the ASN.

Read the Information for Authors.


Kurhausstraße 12
D-97688 Bad Kissingen
Germany
Telefon +49-971-6 4832
Fax +49- 971- 6 8637
Email asn@neurootology.org

 

The use of “rt-pa” for the treatment of sudden and “chronic hearing loss”

Abstract

Eighty patients with sudden hearing loss and seventy patients with a chronical cochlear function decreasing have been treated until now with intravenous infusion of a recombinant glycoprotein analogous tissutal plasminogen activator (rt-PA): 3mg dissolved in 250mg of physiological saline given every 12 hr intravenously.
Specifically excluded were patients with abnormal known coagulation.
No patient was treated longer than 20 days.
At the first observation a medical history and physical examination, a series of hearing tests including audiometry and otoacustic emission (OAE), routine blood examination and a blood clotting factor analysis were performed. During the treatment patients were monitored by hearing tests, OAE, auditory brainstem response, computer tomography and -nuclear magnetic resonance, when necessary. Patients were discharged when their audibility threshold stabilized.
No patient had side effects due to the treatment and the functional results are excellent at all, much more if compared with the protocols of therapy previously used for those kind of diseases.
Tissue plasminogen activator was used for the treatment of sudden hearing loss with remarkable success: this study also shows remarkable success with a very low dose of tPA, compared to the standard dosage used far the treatment of myocardial infarction patients.

Login

Registration

If you are not already registered, please register here for free.

If you are registered but have forgotten your password (or you never had one), click here to recover your password.

Proceedings of

Authors

Archives

2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 |

(bi)gital»